MLTX DEADLINE NOTICE: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages MoonLake Immunotherapeutics Investors with Losses in Excess of $100K to Secure Counsel Before Important December 15 Deadline in Securities Class Action - MLTX

Core Viewpoint - Rosen Law Firm is encouraging investors of MoonLake Immunotherapeutics who incurred losses exceeding $100,000 to seek legal counsel before the December 15, 2025 deadline for a securities class action lawsuit [1][2]. Group 1: Class Action Details - Investors who purchased MoonLake common stock between March 10, 2024, and September 29, 2025, may be eligible for compensation without any upfront fees through a contingency fee arrangement [2]. - To participate in the class action, investors must act before the December 15, 2025 deadline to serve as lead plaintiff, which involves directing the litigation on behalf of other class members [3][6]. - The lawsuit claims that during the class period, the defendants made false or misleading statements regarding the efficacy of their product SLK compared to traditional monoclonal antibodies, leading to investor damages when the truth was revealed [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions for investors [4]. - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020 [4].